Organogenesis Holdings Inc (NASDAQ: ORGO) has seen a decline in its stock price by -1.14 in relation to its previous close of 5.25. However, the company has experienced a 0.68% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-27 that Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O’Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby.
Is It Worth Investing in Organogenesis Holdings Inc (NASDAQ: ORGO) Right Now?
Organogenesis Holdings Inc (NASDAQ: ORGO) has a price-to-earnings ratio of 926.79x that is above its average ratio. Additionally, the 36-month beta value for ORGO is 1.71. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ORGO is 64.38M and currently, short sellers hold a 13.39% ratio of that float. The average trading volume of ORGO on March 14, 2025 was 1.71M shares.
ORGO’s Market Performance
The stock of Organogenesis Holdings Inc (ORGO) has seen a 0.68% increase in the past week, with a 41.80% rise in the past month, and a 41.03% gain in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 9.86% for ORGO. The simple moving average for the last 20 days is 15.63% for ORGO stock, with a simple moving average of 61.42% for the last 200 days.
Analysts’ Opinion of ORGO
Many brokerage firms have already submitted their reports for ORGO stocks, with Lake Street repeating the rating for ORGO by listing it as a “Buy.” The predicted price for ORGO in the upcoming period, according to Lake Street is $5 based on the research report published on June 28, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ORGO reach a price target of $5. The rating they have provided for ORGO stocks is “Overweight” according to the report published on February 07th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ORGO, setting the target price at $5 in the report published on June 15th of the previous year.
ORGO Trading at 35.15% from the 50-Day Moving Average
After a stumble in the market that brought ORGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.65% of loss for the given period.
Volatility was left at 9.86%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares surge +39.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.03% upper at present.
During the last 5 trading sessions, ORGO fell by -0.68%, which changed the moving average for the period of 200-days by +94.68% in comparison to the 20-day moving average, which settled at $4.49. In addition, Organogenesis Holdings Inc saw 62.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORGO starting from Driscoll Michael Joseph, who sale 25,000 shares at the price of $5.10 back on Mar 04 ’25. After this action, Driscoll Michael Joseph now owns 166,879 shares of Organogenesis Holdings Inc, valued at $127,535 using the latest closing price.
Gillheeney Gary S., the President and CEO of Organogenesis Holdings Inc, sale 55,615 shares at $3.36 during a trade that took place back on Dec 13 ’24, which means that Gillheeney Gary S. is holding 3,044,779 shares at $186,866 based on the most recent closing price.
Stock Fundamentals for ORGO
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.74 for the gross margin
The net margin for Organogenesis Holdings Inc stands at 0.0. The total capital return value is set at -0.0. Equity return is now at value 0.26, with 0.18 for asset returns.
Based on Organogenesis Holdings Inc (ORGO), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -0.8.
Currently, EBITDA for the company is -1.28 million with net debt to EBITDA at -8.13. When we switch over and look at the enterprise to sales, we see a ratio of 1.17. The receivables turnover for the company is 4.39for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.69.
Conclusion
In conclusion, Organogenesis Holdings Inc (ORGO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
